- Home
- SFL vs MLYS Comparison
SFL vs MLYS Comparison
Compare SFL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- MLYS
- Stock Information
- Founded
- SFL 2003
- MLYS 2019
- Country
- SFL Bermuda
- MLYS United States
- Employees
- SFL N/A
- MLYS N/A
- Industry
- SFL Marine Transportation
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- MLYS Health Care
- Exchange
- SFL Nasdaq
- MLYS Nasdaq
- Market Cap
- SFL 1.0B
- MLYS 1.0B
- IPO Year
- SFL N/A
- MLYS 2023
- Fundamental
- Price
- SFL $8.31
- MLYS $14.65
- Analyst Decision
- SFL Strong Buy
- MLYS Strong Buy
- Analyst Count
- SFL 2
- MLYS 3
- Target Price
- SFL $14.50
- MLYS $33.00
- AVG Volume (30 Days)
- SFL 971.1K
- MLYS 661.0K
- Earning Date
- SFL 05-20-2025
- MLYS 05-12-2025
- Dividend Yield
- SFL 13.00%
- MLYS N/A
- EPS Growth
- SFL 52.99
- MLYS N/A
- EPS
- SFL 1.01
- MLYS N/A
- Revenue
- SFL $894,061,000.00
- MLYS N/A
- Revenue This Year
- SFL N/A
- MLYS N/A
- Revenue Next Year
- SFL $5.63
- MLYS N/A
- P/E Ratio
- SFL $8.23
- MLYS N/A
- Revenue Growth
- SFL 20.12
- MLYS N/A
- 52 Week Low
- SFL $6.78
- MLYS $8.24
- 52 Week High
- SFL $14.62
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- SFL 56.18
- MLYS 53.36
- Support Level
- SFL $8.09
- MLYS $14.03
- Resistance Level
- SFL $8.45
- MLYS $15.79
- Average True Range (ATR)
- SFL 0.20
- MLYS 0.99
- MACD
- SFL 0.07
- MLYS 0.10
- Stochastic Oscillator
- SFL 82.05
- MLYS 57.57
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.